How to take voclosporin most correctly, full analysis of dosage, taking time and precautions

2026-02-01 22:25:32

Ponatinib is the first generation of targeted drugs and its role in the treatment of chronic myelogenous leukemia

2026-02-01 22:25:32

Comparison of the efficacy of Shafinamide Tablets (Siddaco) and Rasagiline, patient experience and clinical recommendations

2026-02-01 22:25:32

Tarlatamab-Imdelltra one-time treatment cost, patient medication cost and market price analysis

2026-02-01 22:25:32

Summary of telisotuzumab-EMRELIS clinical trial data and efficacy analysis for different indications

2026-02-01 22:25:32

Whether tovorafenib will be included in the medical insurance catalog in 2026 and its reimbursement policy and cost reference instructions

2026-02-01 22:25:32

How many days does a course of vorasidenib-VORANIGO require and detailed instructions on dosage schedule and usage plan?

2026-02-01 22:25:32

Comparative analysis of the differences, indications, efficacy and safety between Zongertinib and Trastuzumab

2026-02-01 22:25:32

Full explanation of vosoritide reimbursement conditions, medical insurance policies, patient fees and purchase process

2026-02-01 22:25:32

Pralsetinib has rewritten the treatment landscape for lung cancer. How do Chinese patients cope with the high costs of not being covered by medical insurance?

2026-02-01 22:25:32

Important Information for Safe Use of Ibrutinib

2026-01-26 06:00:27

Ibrutinib (generic name: Ibrutinib) is a targeted therapy prescription drug that exerts therapeutic effects by inhibiting Bruton's tyrosine kinase (BTK).

Comprehensive description of palbociclib

2026-01-21 02:04:41

Palisib (brand name: IBRANCE) is the world's first commercially available CDK4/6 kinase inhibitor, approved by the US FDA through the accelerated approval pathway on February 3, 2015. Developed by Pfizer, this drug is indicated for use in combination with letrozole in the treatment of postmenopausal women with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as an initial endocrine therapy regimen. Its approval is based on clinical data demonstrating a significant prolongation of progression-free survival (PFS), marking an important advancement in the treatment of hormone receptor-positive advanced breast cancer.